ESMO Public Policy Committee
ESMO represents its members at the political level, working to keep cancer a high priority on the European healthcare agenda.
The ESMO Public Policy Committee addresses political topics of concern to ESMO and its members, with a specific focus on promoting the practice and the profession of medical oncology and diminishing the discrepancies in the quality of cancer care.
ESMO’s approach to advocacy is proactive and hands-on. Through targeted face-to-face meetings with MEPs and government authorities, ESMO creates opportunities to dialogue with decision-makers, listen to their positions, and express to them ESMO’s concerns. Our goal is to propose concrete, practical solutions to address political issues in an effective manner.
The ESMO Public Policy Committee collaborates closely with the ESMO Office in Brussels. It also coordinates its activities with key stakeholders to assure that the oncology community speaks with one united voice.
The committee's objectives are to:
- Gain widespread, full recognition and implementation of medical oncology to assure better multidisciplinary treatment of cancer patients
- Diminish discrepancies in quality of cancer care through the proper development and dissemination of evidence-based clinical practice guidelines
- Establish collaborative networks for cancer care to enhance equal patient access to treatment and care
- Obtain a uniform approval and reimbursement process in Europe for effective anticancer agents
- Improve the frameworks for clinical and translational cancer research to support rapid advancement of new cancer therapies
- Improve health care and research for rare cancers to assure timely and correct diagnosis of patients and their access to the best available care
ESMO’s public policy initiatives include the Recognition of Medical Oncology in Europe, the Rare Cancers Europe initiative, and assuring that the 2013 EU General Data Protection and Clinical Trials Regulations do not create barriers to public health research.
ESMO is currently a member of the European Medicines Agency’s Healthcare Professionals and Transparency in Clinical Trials Data Groups, the European Network for HTA Joint Action 2 Stakeholder Forum, the European Alliance for Personalised Medicine, the European Partnership Action Against Cancer, the European Chronic Disease Alliance, the Non-Communicable Disease Alliance and the Union for International Cancer Control.
- Paolo Casali, Italy
Core Committee Members
- Adamos Adamou, Cyprus
- Jean-Yves Blay, France
- Fortunato Ciardiello, Italy
- Michel Coleman, United Kingdom
- John Crown, Ireland
- Alan Howard, Switzerland
- Margaret Hutka, United Kingdom
- Jose Martin-Moreno, Spain
- Simon Van Belle, Belgium
- Jean-Marie Vlassembrouck, Belgium
Extended Committee Members
- Breast cancer: Serena Di Cosimo, Italy
- Cancer genetics: James Mackay, UK
- Cancer in the elderly: Matti Aapro, Switzerland
- Clinical trials: Marc Buyse, Belgium
- CNS tumours: Andreas Hottinger, Switzerland
- Community oncology: Michalis Karamouzis, Greece
- Community oncology: Stefan Rauh, Luxembourg
- GI cancers: Andres Cervantes, Spain
- Gynecological cancers: Antonio Gonzalez-Martin, Spain
- H&N cancers: Lisa Licitra, Italy
- Haematological cancers: Harry Schouten, Netherlands
- Lung cancer: Marina Garassino, Italy
- Melanoma: Lorenz Jost, Switzerland
- Neuroendocrine tumours: Karim Fizazi, France
- Palliative care: Simon Van Belle, Belgium
- Pathology: Angelo Paolo Dei Tos, Italy
- Prevention: Hans-Jörg Senn, Switzerland
- Prevention: Lawrence von Karsa, France
- Regulatory affairs: Rosa Giuliani, Italy/UK
- Sarcoma: Jean-Yves Blay, France
- Urogenital cancers: Cora Sternberg, Italy